Reuters logo
BRIEF-Genentech reports positive phase 3 results for emicizumab in hemophilia A
July 10, 2017 / 11:32 AM / 4 months ago

BRIEF-Genentech reports positive phase 3 results for emicizumab in hemophilia A

July 10 (Reuters) - Roche Holding Ag:

* Positive phase III results for Genentech’s emicizumab in hemophilia A published in the New England Journal Of Medicine

* Genentech says haven 1 showed emicizumab reduced bleed rate by 87 percent compared with on-demand bypassing agents

* Genentech says all 12 secondary endpoints in haven 1 were positive

* Genentech says data from haven 1 and haven 2 have been submitted for approval consideration to U.S. FDA and European Medicines Agency (EMA) Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below